Validation of UBE2C Protein As a Prognostic Marker in Node-positive Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Jun 11

PMID 19513072

Citations 36

Authors

D Loussouarn

L Campion

F Leclair

M Campone

C Charbonnel

G Ricolleau

W Gouraud

R Bataille

P Jezequel

Affiliations

Soon will be listed here.

Abstract

Background: We recently identified and validated UBE2C RNA as a prognostic marker in 252 node-positive (N+) breast cancers by means of a microarray study. The aim of this study was to validate UBE2C protein as a prognostic marker in N+ breast cancer by immunohistochemistry (IHC).

Methods: To this end, 92 paraffin-embedded blocks were used. The impact of UBE2C IHC value on metastasis-free survival (MFS) and overall survival (OS) was evaluated and compared with Ki-67 and Nottingham prognostic index (NPI) performances.

Results: In accordance with genomic data, UBE2C IHC had a significant impact both on MFS and OS (hazard ratio=6.79 - P=0.002; hazard ratio=7.14 - P=0.009, respectively). Akaike information criterion proved that the prognostic power of UBE2C IHC was stronger than that of Ki-67 (and close to that of NPI). Furthermore, multivariate analyses with NPI showed that, contrary to Ki-67 IHC, UBE2C IHC remained an independent factor, both for MFS (adjusted P=0.02) and OS (adjusted P=0.04).

Conclusion: We confirmed that UBE2C protein measured by IHC could be used as a prognostic marker in N+ breast cancer. The potential predictive interest of UBE2C as a marker of proteasome activity needs further investigations.

Citing Articles

Ubiquitination-Binding Enzyme 2C is Associated with Cancer Development and Prognosis and is a Potential Therapeutic Target.

Zhao M, Li J, Wang R, Mi L, Gu Y, Chen R Onco Targets Ther. 2024; 17:1159-1171.

PMID: 39678016 PMC: 11637980. DOI: 10.2147/OTT.S485053.

The Chromosome Passenger Complex (CPC) Components and Its Associated Pathways Are Promising Candidates to Differentiate Between Normosensitive and Radiosensitive ATM-Mutated Cells.

Dietz A, Subedi P, Azimzadeh O, Duchrow L, Kaestle F, Paetzold J Biomark Insights. 2024; 19:11772719241274017.

PMID: 39493730 PMC: 11528597. DOI: 10.1177/11772719241274017.

UBE2C promotes LUAD progression by ubiquitin-dependent degradation of p53 to inactivate the p53/p21 signaling pathway.

Huang S, Li X Discov Oncol. 2024; 15(1):589.

PMID: 39448441 PMC: 11502638. DOI: 10.1007/s12672-024-01465-4.

expression is elevated in hepatoblastoma and correlates with inferior patient survival.

Nousiainen R, Eloranta K, Isoaho N, Cairo S, Wilson D, Heikinheimo M Front Genet. 2023; 14:1170940.

PMID: 37377594 PMC: 10291054. DOI: 10.3389/fgene.2023.1170940.

UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease.

Paisana E, Cascao R, Custodia C, Qin N, Picard D, Pauck D Neurooncol Adv. 2023; 5(1):vdad048.

PMID: 37215954 PMC: 10195208. DOI: 10.1093/noajnl/vdad048.

References

Ciechanover A . The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans. 2003; 31(2):474-81. DOI: 10.1042/bst0310474. View

Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G . Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14(16):5158-65. DOI: 10.1158/1078-0432.CCR-07-4756. View

Jezequel P, Campone M, Roche H, Gouraud W, Charbonnel C, Ricolleau G . A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat. 2008; 116(3):509-20. DOI: 10.1007/s10549-008-0250-8. View

Ricolleau G, Charbonnel C, Lode L, Loussouarn D, Joalland M, Bogumil R . Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics. 2006; 6(6):1963-75. DOI: 10.1002/pmic.200500283. View

Cusack J . Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev. 2003; 29 Suppl 1:21-31. DOI: 10.1016/s0305-7372(03)00079-3. View

Orlowski R, Dees E . The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003; 5(1):1-7. PMC: 154126. DOI: 10.1186/bcr460. View

Ohta T, Fukuda M . Ubiquitin and breast cancer. Oncogene. 2004; 23(11):2079-88. DOI: 10.1038/sj.onc.1207371. View

Marx C, Yau C, Banwait S, Zhou Y, Scott G, Hann B . Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol. 2007; 71(6):1525-34. DOI: 10.1124/mol.107.034090. View

Mani A, Gelmann E . The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005; 23(21):4776-89. DOI: 10.1200/JCO.2005.05.081. View

10.

Viale G, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, DellOrto P . Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008; 26(34):5569-75. PMC: 2651094. DOI: 10.1200/JCO.2008.17.0829. View

11.

Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F . Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat. 2007; 109(3):491-501. DOI: 10.1007/s10549-007-9673-x. View

12.

Stuart-Harris R, Caldas C, Pinder S, Pharoah P . Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008; 17(4):323-34. DOI: 10.1016/j.breast.2008.02.002. View

13.

Wagner K, Sapinoso L, El-Rifai W, Frierson H, Butz N, Mestan J . Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004; 23(39):6621-9. DOI: 10.1038/sj.onc.1207861. View

14.

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A . UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003; 63(14):4167-73. View

15.

Buness A, Kuner R, Ruschhaupt M, Poustka A, Sultmann H, Tresch A . Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer. Bioinformatics. 2007; 23(17):2273-80. DOI: 10.1093/bioinformatics/btm340. View

16.

Chen L, Madura K . Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 2005; 65(13):5599-606. DOI: 10.1158/0008-5472.CAN-05-0201. View

17.

Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A . Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol. 2003; 163(5):1979-84. PMC: 1892409. DOI: 10.1016/S0002-9440(10)63556-0. View

18.

Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T . Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat. 2006; 104(1):21-30. DOI: 10.1007/s10549-006-9393-7. View

19.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B . Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008; 10(4):R65. PMC: 2575538. DOI: 10.1186/bcr2124. View

20.

Ma X, Salunga R, Tuggle J, Gaudet J, Enright E, McQuary P . Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003; 100(10):5974-9. PMC: 156311. DOI: 10.1073/pnas.0931261100. View